Tormentic acid reduces vascular smooth muscle cell proliferation and survival

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 50-54

  Fogo, Anelize S ^a   Antonioli, Eliane ^b   Calixto, João B ^c   Campos, Alexandre H ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Albert Einstein Research and Education Institute   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Apoptosis; Endothelial cell; Proliferation; Tormentic acid; Vascular smooth muscle cell

Indexed keywords

TORMENTIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; UMBILICAL CORD; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; CATTLE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; TRITERPENES;

EID: 67449146879     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.05.009     Document Type: Article

References (33)

1. Banno N., Akihisa T., Tokuda H., Yasukawa K., Higashihara H., Ukiya M., Watanabe K., Kimura Y., Hasegawa J., and Nishino H. Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor promoting effects. Biosci. Biotechnol. Biochem. 68 (2004) 85-90
2. Beirith A., Santos A.R., Calixto J.B., Hess S.C., Messana I., Ferrari F., and Yunes R.A. Study of the antinociceptive action of the ethanolic extract and the triterpene 24-hydroxytormentic acid isolated from the stem bark of Ocotea suaveolens. Planta Med. 65 (1999) 50-55
3. Bortalanza L.B., Ferreira J., Hess S.C., Delle Monache F., Yunes R.A., and Calixto J.B. Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice. Eur. J. Pharmacol. 453 (2002) 203-208
4. Cichewicz R.H., and Kouzi S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 24 (2004) 90-114
5. Dzau V.J., Braun-Dullaeus R.C., and Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8 (2002) 1249-1256
6. Finn A.V., Nakazawa G., Joner M., Kolodgie F.D., Mont E.K., Gold H.K., and Virmani R. Vascular responses to drug eluting stents. Importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1500-1510
7. Fuke S., Maekawa K., Kawamoto K., Saito H., Sato T., Hioka T., and Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ. J. 71 (2007) 220-225
8. Gao H., Wu L., Kuroyanagi M., Harada K., Kawahara N., Nakane T., Umehara K., Hirasawa A., and Nakamura Y. Antitumor-promoting constituents from Chaenomeles sinensis KOEHNE and their activities in JB6 mouse epidermal cells. Chem. Pharm. Bull. 51 (2003) 1318-1321
9. Jin J.L., Lee Y.Y., Heo J.E., Lee S., Kim J.M., and Yun-Choi H.S. Antiplatelet pentacyclic triterpenoids from leaves of Campsis grandiflora. Arch. Pharm. Res. 27 (2004) 376-380
10. Kakar P., and Lip G.Y. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Exp. Rev. Cardiovasc. Ther. 5 (2007) 441-450
11. Li J., Guo W.J., and Yang Q.Y. Effects of ursolic acid and oleanolic acid on human colon carcinoma cell line HCT15. World J. Gastroenterol. 8 (2002) 493-495
12. Li J.J., Li J., Nan J.L., Li Z., Zhen X., Mu C.W., Dai J., and Zhang C.Y. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects. Med. Hypotheses 69 (2007) 1004-1009
13. Liu J. Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49 (1995) 57-68
14. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., and Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349 (2003) 1315-1323
15. Murakami C., Ishijima K., Hirota M., Sakaguchi K., Yoshida H., and Mizushina Y. Novel anti-inflammatory compounds from Rubus sieboldii, triterpenoids, are inhibitors of mammalian DNA polymerases. Biochim. Biophys. Acta 1596 (2002) 193-200
16. Novotny L., Vachalkova A., and Biggs D. Ursolic acid: an anti-tumorigenic and chemopreventive activity. Minireview Neoplasma 48 (2001) 241-246
17. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75 (1995) 487-517
18. Parry T.J., Brosius R., Thyagarajan R., Carter D., Argentieri D., Falotico R., and Siekierka J. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur. J. Pharmacol. 524 (2005) 19-29
19. Pollman M.J., Yamada T., Horiuchi M., and Gibbons G.H. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ. Res. 79 (1996) 748-756
20. Ross R. The pathogenesis of atherosclerosis-an update. N. Engl. J. Med. 314 (1986) 488-500
21. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
22. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138 (1999) S419-420
23. Schwartz S.M., Campbell G.R., and Campbell J.H. Replication of smooth muscle cells in vascular disease. Circ. Res. 58 (1986) 427-444
24. Shishodia S., Majumdar S., Banerjee S., and Aggarwal B.B. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. 63 (2003) 4375-4383
25. Stegemann J.P., Hong H., and Nerem R.M. Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype. J. Appl. Physiol. 98 (2005) 2321-2327
26. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., and Russell M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350 (2004) 221-231
27. Subbaramaiah K., Michaluart P., Sporn M.B., and Dannenberg A.J. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res. 60 (2000) 2399-2404
28. Suh N., Honda T., Finlay H.J., Barchowsky A., Williams C., Benoit N.E., Xie Q.W., Nathan C., Gribble G.W., and Sporn M.B. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 58 (1998) 717-723
29. Tran H., and Anand S.S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 292 (2004) 1867-1874
30. Win H.K., Caldera A.E., Maresh K., Lopez J., Rihal C.S., Parikh M.A., Granada J.F., Marulkar S., Nassif D., Cohen D.J., and Kleiman N.S. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
31. Winters G.L. The pathology of heart allograft rejection. Arch. Pathol. Lab. Med. 115 (1991) 266-272
32. Yoshida T., and Owens G.K. Molecular determinants of vascular smooth muscle cell diversity. Circ. Res. 96 (2005) 280-291
33. Zhang Q., Chang Z., and Wang Q. Ursane triterpenoids inhibit atherosclerosis and xanthoma in LDL receptor knockout mice. Cardiovasc. Drugs Ther. 20 (2006) 349-357